創薬力強化で戦略目標　「骨太」に反映へ―政府有識者会議

　海外で使われている薬が日本で実用化されていない「ドラッグ・ロス」などの解消を目指す政府の有識者会議が２２日開かれ、創薬力強化のための戦略目標をまとめた。政府が６月ごろに策定する経済財政運営の基本方針「骨太の方針」に反映される見通し。
　戦略目標は▽最新医薬品の迅速な提供▽研究強化と人材誘致▽投資環境の整備―を柱とし、国際基準に合わせる形で薬事規制を見直すことで、ドラッグ・ロスや国内の承認が遅れる「ドラッグ・ラグ」の解消につなげる。また、患者数が少なく採算性が乏しい難病と希少疾病用の医薬品の開発も促進させる。（2024/05/22-15:48）

A government expert panel compiled Wednesday a set of strategic goals for strengthening Japan's drug discovery capabilities, which will be reflected in the government's economic and fiscal policy guidelines to be drawn up around June.
   The strategic goals are aimed at resolving "drug loss," in which drugs approved overseas are not used in Japan, and "drug lag," or delays in domestic drug approval processes, by reviewing Japan's pharmaceutical regulations in line with global standards.
   The goals are centered around swiftly providing cutting-edge drugs, boosting research, attracting talent and enhancing the investment environment. They are also aimed at promoting the development of treatments for rare and intractable diseases, which are often unprofitable due to the small number of patients.
   The government hopes to attract professionals with drug discovery expertise from international pharmaceutical firms to Japan so that they can lead drug research and development. It plans to establish a public-private council including foreign firms and hold preparatory discussions on the matter as early as August.
   "We will work diligently to implement (the goals) to improve our drug discovery capabilities," Deputy Chief Cabinet Secretary Hideki Murai, who chaired the expert panel meeting, said.